中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities

文献类型：期刊论文

作者Huang, Feng4; Tian, Tian4; Wu, Yizhe4; Che, Jinxin4; Yang, Haiyan1,5; Dong, Xiaowu2,3,4
刊名MINI-REVIEWS IN MEDICINAL CHEMISTRY
出版日期2021
卷号21
ISSN号1389-5575
关键词Isocitrate dehydrogenase 2 IDH2 mutant inhibitors structure-activity relationship blood cance
DOI10.2174/1389557520666201130102724
通讯作者Yang, Haiyan(haiyanyang1125@163.com) ; Dong, Xiaowu(dongxw@zju.edu.cn)
英文摘要Tumor cells frequently reprogram cellular metabolism from oxidative phosphorylation to glycolysis. Isocitrate dehydrogenase 2 (IDH2) has been intensively studied due to its involvement in the metabolic activity of cancer cells. Mutations in IDH2 promote neomorphic activity through the generation of oncometabolite 2-hydroxyglutarate (2- HG). The overproduced 2-HG can competitively inhibit a-KG-dependent dioxygenases to trigger cell differentiation disorders, a major cause of blood tumors. This review outlines recent progress in the identification of IDH2 inhibitors in blood cancer to provide a reference for ongoing and future clinical studies.
WOS关键词ACUTE MYELOID-LEUKEMIA ; IDH2 MUTATIONS ; MYELODYSPLASTIC SYNDROMES ; PROGNOSTIC-SIGNIFICANCE ; MUTANT IDH2 ; CANCER ; 2-HYDROXYGLUTARATE ; MECHANISMS ; ENASIDENIB ; GENES
资助项目Leading Talent of Ten Thousand Plan - National High-Level Talents Special Support Plan ; National Natural Science Foundation of China[81673294] ; National Natural Science Foundation of China[81503110] ; China Postdoctoral Science Foundation[2019M652123] ; China Postdoctoral Science Foundation[2019M652124]
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者BENTHAM SCIENCE PUBL LTD
WOS记录号WOS:000652154800007
资助机构Leading Talent of Ten Thousand Plan - National High-Level Talents Special Support Plan ; National Natural Science Foundation of China ; China Postdoctoral Science Foundation
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/122146]  
专题中国科学院合肥物质科学研究院
通讯作者Yang, Haiyan; Dong, Xiaowu
作者单位1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou 310011, Peoples R China
2.Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
3.Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310058, Peoples R China
4.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou Inst Innovat Med, Hangzhou 310058, Peoples R China
5.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou 310000, Peoples R China
推荐引用方式
GB/T 7714		 Huang, Feng,Tian, Tian,Wu, Yizhe,et al. Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY,2021,21.
APA Huang, Feng,Tian, Tian,Wu, Yizhe,Che, Jinxin,Yang, Haiyan,&Dong, Xiaowu.(2021).Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.MINI-REVIEWS IN MEDICINAL CHEMISTRY,21.
MLA Huang, Feng,et al."Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities".MINI-REVIEWS IN MEDICINAL CHEMISTRY 21(2021).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。